SCHEMBL2884938

SCHEMBL2884938

Cc1cc(C)c(P(Cl)Cl)c(C)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAPGEF4 Q8WZA2 9/20 0.39
ALDH1A1 P00352 3/20 0.33
KDM4E B2RXH2 2/20 0.33
LMNA P02545 1/20 0.33
GAA P10253 1/20 0.33
MAPT P10636 1/20 0.33
CYP1A2 P05177 1/20 0.32
CYP2A6 P11509 1/20 0.32
TSHR P16473 1/20 0.32
TP53 P04637 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
FFAR4 Q5NUL3 1/20 0.30
CA1 P00915 1/20 0.30
CA2 P00918 1/20 0.30
MMP1 P03956 1/20 0.30
MMP2 P08253 1/20 0.30
MMP9 P14780 1/20 0.30
MMP8 P22894 1/20 0.30
MMP13 P45452 1/20 0.30
GRIN2D O15399 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1536733 0.83 RAPGEF4 (0.38) RAPGEF4
SCHEMBL5362839 0.82 RAPGEF4 (0.39) RAPGEF4ALDH1A1KDM4ELMNAGAA
SCHEMBL9329893 0.78 RAPGEF4 (0.42) RAPGEF4ALDH1A1FFAR4CA1CA2
SCHEMBL1043330 0.78 RAPGEF4 (0.39) RAPGEF4ALDH1A1LMNACYP1A2TSHR
SCHEMBL11785341 0.75 RAPGEF4 (0.43) RAPGEF4ALDH1A1KDM4ELMNAGAA
SCHEMBL301709 0.75 RAPGEF4 (0.43) RAPGEF4ALDH1A1KDM4ELMNAGAA
Silver SCHEMBL31010581 0.73 RAPGEF4 (0.41) RAPGEF4ALDH1A1KDM4ELMNAGAA
SCHEMBL31325570 0.73 RAPGEF4 (0.41) RAPGEF4ALDH1A1KDM4ELMNAGAA
Iodide SCHEMBL9662368 0.73 RAPGEF4 (0.41) RAPGEF4ALDH1A1KDM4ELMNAGAA
Bromide SCHEMBL3679642 0.73 RAPGEF4 (0.41) RAPGEF4ALDH1A1KDM4ELMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103613618-B A kind of [2.2] multiply biology and preparation method thereof and application to ring JIANG University OF TECHNOLOGY (CN) 2015-10-28 CN claimed
CN-103613618-A [2.2] paracyclophane derivative as well as preparation method and application thereof UNIV ZHEJIANG TECHNOLOGY 2014-03-05 CN claimed
EP-1354886-B1 Process for the preparation of tertiary phosphines SALTIGO GMBH (DE) 2009-08-26 EP claimed
US-7230136-B2 Reacting phosphorus halide with organomagnesium compound in presence of copper compound LANXESS DEUTSCHLAND GMBH (DE) 2007-06-12 US claimed
US-20030229240-A1 Reacting phosphorus halide with organomagnesium compound in presence of copper compound LANXESS DEUTSCHLAND GMBH (DE) 2003-12-11 US claimed
EP-1354886-A1 Process for the preparation of tertiary phosphines Bayer Aktiengesellschaft (DE) 2003-10-22 EP claimed
CN-103613618-B A kind of [2.2] multiply biology and preparation method thereof and application to ring JIANG University OF TECHNOLOGY (CN) 2015-10-28 CN disclosed
CN-103613618-A [2.2] paracyclophane derivative as well as preparation method and application thereof UNIV ZHEJIANG TECHNOLOGY 2014-03-05 CN disclosed
US-7847126-B2 prepared by reacting phosphorus halide with organomagnesium compound in presence of copper compound; di(tert-butyl)phenylphosphonium tetrafluoroborate, for example LANXESS DEUTSCHLAND GMBH (DE) 2010-12-07 US disclosed
EP-1354886-B1 Process for the preparation of tertiary phosphines SALTIGO GMBH (DE) 2009-08-26 EP disclosed
US-20070299273-A1 prepared by reacting phosphorus halide with organomagnesium compound in presence of copper compound; di(tert-butyl)phenylphosphonium tetrafluoroborate, for example LANXESS DEUTSCHLAND GMBH (DE) 2007-12-27 US disclosed
US-7250519-B2 Method for the production of arylamines MERCK PATENT GMBH (DE) 2007-07-31 US disclosed
US-7230136-B2 Reacting phosphorus halide with organomagnesium compound in presence of copper compound LANXESS DEUTSCHLAND GMBH (DE) 2007-06-12 US disclosed
US-20050054854-A1 Method for the production of arylamines MERCK PATENT GMBH (DE) 2005-03-10 US disclosed
EP-1442007-A1 METHOD FOR THE PRODUCTION OF ARYLAMINES Covion Organic Semiconductors GmbH (DE) 2004-08-04 EP disclosed
US-20030229240-A1 Reacting phosphorus halide with organomagnesium compound in presence of copper compound LANXESS DEUTSCHLAND GMBH (DE) 2003-12-11 US disclosed
EP-1354886-A1 Process for the preparation of tertiary phosphines Bayer Aktiengesellschaft (DE) 2003-10-22 EP disclosed
WO-2003078478-A1 CATALYSTS FOR OLEFIN POLYMERIZATION E.I. DU PONT DE NEMOURS AND COMPANY (US) 2003-09-25 WO disclosed
WO-2003076450-A1 CATALYSTS FOR OLEFIN POLYMERIZATION E.I. DU PONT DE NEMOURS AND COMPANY (US) 2003-09-18 WO disclosed
WO-2003037844-A1 METHOD FOR THE PRODUCTION OF ARYLAMINES COVION ORGANIC SEMICONDUCTORS GMBH (DE) 2003-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054854-A1 Method for the production of arylamines DDT, PDS5A, KMO RAPGEF4 3564/4885ALDH1A1 2177/4885KDM4E 1811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.